

AMENDMENT TRANSMITTAL LETTER (Large Entity)

Applicant(s): Yves A. Chantigny et al

Docket No.

023118A/US (17166)

| | | | | | |
|-------------------------------|-----------------------------|-----------------------------|-----------------------|------------------------|--------------------------|
| Application No. 10/615,126 | Filing Date July 8, 2003 | Examiner Nyeemah Grazier | Customer No. 26648 | Group Art Unit 1626 | Confirmation No. 8071 |
|-------------------------------|-----------------------------|-----------------------------|-----------------------|------------------------|--------------------------|

O I P
Invention: MODULATORS OF THE GLUCOCORTICOID RECEPTOR
JAN 06 2006
PATENT & TRADEMARK OFFICE
U.S. DEPARTMENT OF COMMERCE

COMMISSIONER FOR PATENTS:

Transmitted herewith is an amendment in the above-identified application.


The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED

| | CLAIMS REMAINING AFTER AMENDMENT | HIGHEST # PREV. PAID FOR | NUMBER EXTRA CLAIMS PRESENT | RATE | ADDITIONAL FEE |
|--|-------------------------------------|-----------------------------|--------------------------------|------------|-------------------|
| TOTAL CLAIMS | 79 - | 66 = | 13 | x \$50.00 | \$650.00 |
| INDEP. CLAIMS | 1 - | 3 = | 0 | x \$200.00 | \$0.00 |
| Multiple Dependent Claims (check if applicable) <input type="checkbox"/> | | | | | \$0.00 |
| TOTAL ADDITIONAL FEE FOR THIS AMENDMENT | | | | | \$650.00 |

- No additional fee is required for amendment.
- Please charge Deposit Account No. 19-1025 in the amount of \$650.00
- A check in the amount of _____ to cover the filing fee is enclosed.
- The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 19-1025
 - Any additional filing fees required under 37 C.F.R. 1.16.
 - Any patent application processing fees under 37 CFR 1.17.
- Payment by credit card. Form PTO-2038.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.



Signature

Brandon S. Boss, Reg. No. 46,567
Corporate Counsel
Pfizer Inc.
P.O. Box 1027
Chesterfield, Missouri 63006
314.274.3662

Dated: January 4, 2006

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

January 4, 2006

(Date)



Signature of Person Mailing Correspondence

Linda K. Cooper

Typed or Printed Name of Person Mailing Correspondence

cc:



TRANSMITTAL LETTER
(General - Patent Pending)

Docket No.
023118A (17166)

In Re Application Of: Yves A. Chantigny et al.

| | | | | | |
|-----------------|---------------|-----------------|--------------|----------------|------------------|
| Application No. | Filing Date | Examiner | Customer No. | Group Art Unit | Confirmation No. |
| 10/615,126 | July 8,, 2003 | Nyeemah Grazier | 26648 | 1626 | 8071 |

Title: MODULATORS OF THE GLUCOCORTICOID RECEPTOR

COMMISSIONER FOR PATENTS:

Transmitted herewith is:

Amendment Transmittal; Response to Office Action (\$650.00); Itemized Postcard.

in the above identified application.

No additional fee is required.

A check in the amount of _____ is attached.

The Director is hereby authorized to charge and credit Deposit Account No. 19-1025 as described below.

Charge the amount of \$650.00

Credit any overpayment.

Charge any additional fee required.

Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Signature

Brandon S. Boss, Reg. No. 46,567
Corporate Counsel
Pfizer Inc.
P.O. Box 1027
Chesterfield, Missouri 63006
314.274.3662

Dated: January 4, 2006

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

January 4, 2006

(Date)

Signature of Person Mailing Correspondence

Linda K. Cooper

Typed or Printed Name of Person Mailing Correspondence

CC:



hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on January 4, 2006.

Linda Cooper

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/615,126 Confirmation No.: 8071
First Named Inventor : Chantigny
Filing Date : 07/08/2003
Art Unit : 1626
Examiner : Grazier, Nyeemah
Title : Glucocorticoid Receptor Modulators

RESPONSE AND AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INTRODUCTORY COMMENTS

This response to the Office Action of October 4, 2005 is being timely filed by the due date.

AMENDMENTS TO THE CLAIMS appear on page 2.

REMARKS begin on page 20.

01/09/2006 MBELETE1 00000041 191025 10615126

01 FC:1202 650.00 DA